Experience with oesophageal cancer: a ten-year single centre study reflecting daily practice.

ISRN gastroenterology Pub Date : 2013-04-24 Print Date: 2013-01-01 DOI:10.1155/2013/205417
R J L F Loffeld, P E P Dekkers
{"title":"Experience with oesophageal cancer: a ten-year single centre study reflecting daily practice.","authors":"R J L F Loffeld,&nbsp;P E P Dekkers","doi":"10.1155/2013/205417","DOIUrl":null,"url":null,"abstract":"<p><p>Introduction. Studied patients with oesophageal cancer do not represent normal daily presentation. Aim. A retrospective study was done in all consecutive patients in order to describe presentation, treatment, and survival. Patients. All patients in a ten-year period were included. Patients were grouped in three groups. Group 1: no metastases and potentially curable, dead, or alive at time of evaluation. Group 2: patients presenting with metastases and treated with palliative chemotherapy, and group 3: patients with or without metastases but untreatable because of low Karnofsky index or important comorbidity rendering treatment not feasible. Results. One hundred thirty one evaluable patients were included. There was no difference in histological type of the tumour. Patients in group 3 were significantly older. Survival was not different between groups 2 and 3. Survival in group 1 was significantly longer (P < 0.0001) compared with groups 2 and 3. Patients in group 1 received treatment with chemoradiation and surgery. Patients in groups 2 and 3 were more often treated with palliative chemotherapy and endoscopic stenting. Conclusion. The overall survival of oesophageal cancer in normal daily life is poor. Supportive care seems to be the best treatment option in patients with metastases or low Karnofsky index. Palliative chemotherapy does not add to overall survival.</p>","PeriodicalId":89397,"journal":{"name":"ISRN gastroenterology","volume":"2013 ","pages":"205417"},"PeriodicalIF":0.0000,"publicationDate":"2013-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/205417","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/205417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Introduction. Studied patients with oesophageal cancer do not represent normal daily presentation. Aim. A retrospective study was done in all consecutive patients in order to describe presentation, treatment, and survival. Patients. All patients in a ten-year period were included. Patients were grouped in three groups. Group 1: no metastases and potentially curable, dead, or alive at time of evaluation. Group 2: patients presenting with metastases and treated with palliative chemotherapy, and group 3: patients with or without metastases but untreatable because of low Karnofsky index or important comorbidity rendering treatment not feasible. Results. One hundred thirty one evaluable patients were included. There was no difference in histological type of the tumour. Patients in group 3 were significantly older. Survival was not different between groups 2 and 3. Survival in group 1 was significantly longer (P < 0.0001) compared with groups 2 and 3. Patients in group 1 received treatment with chemoradiation and surgery. Patients in groups 2 and 3 were more often treated with palliative chemotherapy and endoscopic stenting. Conclusion. The overall survival of oesophageal cancer in normal daily life is poor. Supportive care seems to be the best treatment option in patients with metastases or low Karnofsky index. Palliative chemotherapy does not add to overall survival.

Abstract Image

食管癌的经验:一项反映日常实践的十年单中心研究。
介绍。所研究的食管癌患者的日常表现不正常。的目标。对所有连续患者进行回顾性研究,以描述其表现、治疗和生存。病人。所有10年内的患者都被纳入研究。患者分为三组。组1:无转移,在评估时可能治愈,死亡或活着。第2组:出现转移并接受姑息性化疗的患者;第3组:有或无转移但因低Karnofsky指数或重要合并症而无法治疗的患者。结果。纳入131例可评估患者。肿瘤的组织学类型无差异。第3组患者明显衰老。2组和3组的生存率无差异。与2、3组相比,1组患者的生存期明显延长(P < 0.0001)。第一组患者接受放化疗和手术治疗。第2组和第3组患者更常接受姑息性化疗和内镜支架置入术。结论。食管癌患者在日常生活中的总体生存率较差。支持治疗似乎是转移或低Karnofsky指数患者的最佳治疗选择。姑息性化疗不会增加总生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信